JP2022519082A5 - - Google Patents

Info

Publication number
JP2022519082A5
JP2022519082A5 JP2021544622A JP2021544622A JP2022519082A5 JP 2022519082 A5 JP2022519082 A5 JP 2022519082A5 JP 2021544622 A JP2021544622 A JP 2021544622A JP 2021544622 A JP2021544622 A JP 2021544622A JP 2022519082 A5 JP2022519082 A5 JP 2022519082A5
Authority
JP
Japan
Prior art keywords
seq
antibody according
sequence
human
multispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021544622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519082A (ja
Filing date
Publication date
Priority claimed from NL2022494A external-priority patent/NL2022494B1/en
Application filed filed Critical
Priority claimed from PCT/NL2020/050051 external-priority patent/WO2020159368A1/en
Publication of JP2022519082A publication Critical patent/JP2022519082A/ja
Publication of JP2022519082A5 publication Critical patent/JP2022519082A5/ja
Priority to JP2024218893A priority Critical patent/JP2025032324A/ja
Pending legal-status Critical Current

Links

JP2021544622A 2019-02-01 2020-01-30 新規cd40結合抗体 Pending JP2022519082A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218893A JP2025032324A (ja) 2019-02-01 2024-12-13 新規cd40結合抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2022494 2019-02-01
NL2022494A NL2022494B1 (en) 2019-02-01 2019-02-01 Novel CD40-binding antibodies
NL2024087 2019-10-23
NL2024087 2019-10-23
PCT/NL2020/050051 WO2020159368A1 (en) 2019-02-01 2020-01-30 Novel cd40-binding antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218893A Division JP2025032324A (ja) 2019-02-01 2024-12-13 新規cd40結合抗体

Publications (2)

Publication Number Publication Date
JP2022519082A JP2022519082A (ja) 2022-03-18
JP2022519082A5 true JP2022519082A5 (cg-RX-API-DMAC10.html) 2022-12-27

Family

ID=71840475

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544622A Pending JP2022519082A (ja) 2019-02-01 2020-01-30 新規cd40結合抗体
JP2024218893A Ceased JP2025032324A (ja) 2019-02-01 2024-12-13 新規cd40結合抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218893A Ceased JP2025032324A (ja) 2019-02-01 2024-12-13 新規cd40結合抗体

Country Status (11)

Country Link
US (1) US20220135694A1 (cg-RX-API-DMAC10.html)
EP (1) EP3917960A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022519082A (cg-RX-API-DMAC10.html)
KR (1) KR20210141466A (cg-RX-API-DMAC10.html)
CN (1) CN113993893A (cg-RX-API-DMAC10.html)
AU (1) AU2020216250A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021015238A8 (cg-RX-API-DMAC10.html)
CA (1) CA3128148A1 (cg-RX-API-DMAC10.html)
MX (1) MX2021009285A (cg-RX-API-DMAC10.html)
SG (1) SG11202108141VA (cg-RX-API-DMAC10.html)
WO (1) WO2020159368A1 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202002581D0 (en) 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
ES2943063T5 (en) * 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
MX2023006832A (es) * 2020-12-10 2023-08-22 Lava Therapeutics N V Anticuerpos que se unen a receptores de linfocitos t gamma-delta.
KR20230160253A (ko) 2021-02-17 2023-11-23 감마델타 테라퓨틱스 엘티디 항-tcr 델타 가변 1 항체
MX2023009544A (es) 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.
EP4355781A1 (en) 2021-06-18 2024-04-24 Autolus Limited Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases
WO2023025194A1 (zh) * 2021-08-24 2023-03-02 江苏恒瑞医药股份有限公司 Fap/cd40结合分子及其医药用途
WO2023046037A1 (zh) * 2021-09-24 2023-03-30 正大天晴药业集团股份有限公司 抗cd40抗体及其用途
JP2024538958A (ja) 2021-10-21 2024-10-28 ラヴァ・セラピューティクス・エヌ・ヴイ ガンマデルタt細胞活性化抗体の使用
JP2025504363A (ja) * 2022-01-05 2025-02-12 インヒブルクス バイオサイエンシズ インコーポレイテッド γδT細胞結合ポリペプチド及びその使用
CA3208653A1 (en) * 2022-02-17 2022-08-25 Mihriban Tuna Multispecific anti-tcr delta variable 1 antibodies
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprising antibodies that bind gamma-delta t cell receptors
US20250376535A1 (en) * 2022-06-28 2025-12-11 Beijing Starmab Biomed Technology Ltd Monospecific and multi-specific antibodies
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
WO2024092150A2 (en) * 2022-10-26 2024-05-02 Providence Health & Services - Oregon Combination therapies utilizing microbially-expanded gamma delta t cells and t cell engaging biologics
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
KR20260004605A (ko) * 2024-07-01 2026-01-09 주식회사 피비이뮨테라퓨틱스 길항성 항-cd40 인간화 항체

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028481A2 (en) * 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
NO2699601T3 (cg-RX-API-DMAC10.html) * 2011-04-21 2018-06-16
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
BR112019000512A2 (pt) * 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
US11220550B2 (en) * 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity

Similar Documents

Publication Publication Date Title
JP5723279B2 (ja) 抗cxcr4抗体および癌治療のためのそれらの使用
CN101939336B (zh) Axl抗体
US9150657B2 (en) Anti-EPHA2 antibody
JP2021508469A5 (cg-RX-API-DMAC10.html)
TWI854953B (zh) 抗cd3抗體及含有該抗體的分子、及其製造方法
EP3020812B1 (en) Novel anti-dr5 antibody
JP2018503380A5 (cg-RX-API-DMAC10.html)
CN103189392B (zh) ErbB3结合抗体
EP3645742A2 (en) Anti-ror1 antibodies and methods of making and using thereof
JP2020501531A5 (cg-RX-API-DMAC10.html)
HRP20150256T1 (hr) Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe
WO2016179335A1 (en) Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
JP2010532169A5 (cg-RX-API-DMAC10.html)
JP2018502050A5 (cg-RX-API-DMAC10.html)
CN116041530A (zh) 多特异性抗体及其制备和使用方法
JP2009545325A5 (cg-RX-API-DMAC10.html)
WO2020156555A1 (zh) 抗her2的双特异性抗体及其应用
JP2020516309A5 (cg-RX-API-DMAC10.html)
JP2024533457A5 (cg-RX-API-DMAC10.html)
JP2024507937A5 (cg-RX-API-DMAC10.html)
EP4242231A1 (en) Anti-siglec-15 antibody and application thereof in preparing drug
TW202340250A (zh) 標靶cd25的抗體及其製備方法和應用
CN118632871A (zh) 抗vista抗体及其用途
HK40018991A (en) Multi-specific antibodies and methods of making and using thereof
NZ739252A (en) Monoclonal antibodies against bcma